Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-813160 with Nivolumab and Chemotherapy in Pancreatic Cancer
NCT03496662Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BMS-813160 in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Safety of the Combination and Objective Response Rate. Started Aug 2018; status: completed.
02
Drugs
BMS-813160
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03496662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496662.